- Home
- SNCY vs GHRS Comparison
SNCY vs GHRS Comparison
Compare SNCY & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | GHRS |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.5M | 892.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNCY | GHRS |
|---|---|---|
| Price | $15.29 | $15.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $19.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 737.6K | 652.3K |
| Earning Date | 02-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.51 | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $1,106,213,000.00 | N/A |
| Revenue This Year | $6.16 | N/A |
| Revenue Next Year | $8.41 | N/A |
| P/E Ratio | $14.60 | ★ N/A |
| Revenue Growth | ★ 4.27 | N/A |
| 52 Week Low | $8.10 | $7.98 |
| 52 Week High | $18.59 | $20.50 |
Technical Indicators
Market Signals| Indicator | SNCY | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 57.73 |
| Support Level | $14.19 | $13.50 |
| Resistance Level | $15.86 | $18.17 |
| Average True Range (ATR) | 0.49 | 1.28 |
| MACD | -0.01 | 0.43 |
| Stochastic Oscillator | 66.73 | 50.58 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.